Colesevelam hydrochloride in the management of dyslipidemia

References

• American Heart Association. American Heart Association Heart Disease and Stroke Statistics – 2005 Update. Dallas, Texas, USA (2004).
   Google Scholar
• Wilson P, D’Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation97, 1837–1847 (1998).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• ALLHAT officers and coordinators for the ALLHAT collaborative research group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA288, 2998–3007 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT–LLA): a multicentre randomised controlled trial. Lancet361, 1149–1158 (2003) (9364).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360, 1623–1630 (2002) (9346).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet360(9362), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110(2), 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Ahrens EH Jr, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J. Lab. Clin. Med.78(1), 94–121 (1971).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Packard CJ, Bicker S et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N. Engl. J. Med.302(22), 1219–1222 (1980).
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA251(3), 351–364 (1984).
   PubMed Web of Science ®Google Scholar
• Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med.332(8), 512–521 (1995).
   PubMed Web of Science ®Google Scholar
• Watts GF, Lewis B, Brunt JN et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet339, 563–569 (1992) (8793).
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med.323(19), 1289–1298 (1990).
   PubMed Web of Science ®Google Scholar
• Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? N. Engl. J. Med.332(17), 1125–1131 (1995).
   PubMed Web of Science ®Google Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin. Pharmacother.4(5), 779–790 (2003).
   PubMed Web of Science ®Google Scholar
• Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother.35(7–8), 898–907 (2001).
   PubMed Web of Science ®Google Scholar
• Donovan JM, Von Bergmann K, Setchell KD et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig. Dis. Sci.50(7), 1232–1238 (2005).
   PubMed Web of Science ®Google Scholar
• Steinmetz KL. Colesevelam hydrochloride. Am. J. Health Syst. Pharm.59(10), 932–939 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med.159(16), 1893–1900 (1999).
   PubMed Web of Science ®Google Scholar
• Arrese M, Trauner M, Sacchiero RJ et al. Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. Hepatology28(4), 1081–1087 (1998).
   PubMed Web of Science ®Google Scholar
• Heller DP, Burke SK, Davidson DM et al. Absorption of colesevelam hydrochloride in healthy volunteers. Ann. Pharmacother.36(3), 398–403 (2002).
   PubMed Web of Science ®Google Scholar
• Insull W Jr, Toth P, Mullican W et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc.76(10), 971–982 (2001).
   PubMed Web of Science ®Google Scholar
• Blake GJ, Otvos GJ, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation106(15), 1930–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Kuller L, Arnold A, Tracy R et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol.22(7), 1175–1180 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis185(2),327–330 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Toth P, Weiss S et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin. Cardiol.24(6), 467–474 (2001).
   PubMed Web of Science ®Google Scholar
• Hunninghake D, Insull W, Toth P et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis158(2), 407–416 (2001).
   PubMed Web of Science ®Google Scholar
• Knapp HH, Schrott H, Ma P et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med.110(5), 352–360 (2001).
   PubMed Web of Science ®Google Scholar
• Bays H JM, Abby S, Colesevelam. HCl Added to a Statin: Effects on Lipid Profile and hsCRP. American Heart Association Scientific Sessions. Dallas, TX, USA (2005) (Abstract #1087).
   Google Scholar
• Xydakis AM, Guyton JR, Chiou P et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am. J. Cardiol.94(6), 795–797 (2004).
   PubMed Web of Science ®Google Scholar
• Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther.12(4), 306–310 (2005).
   PubMedGoogle Scholar
• Insert SP, Mosby’s Drug Consult.
   Google Scholar
• Donovan JM, Stypinski D, Stiles MR et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc. Drugs Ther.14(6), 681–690 (2000).
   PubMed Web of Science ®Google Scholar
• Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin. Pharmacokinet.43(13), 943–950 (2004).
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA279(18), 1458–1462 (1998).
   PubMed Web of Science ®Google Scholar
• Puleston J, Morgan H, Andreyev J. New treatment for bile salt malabsorption. Gut54(3), 441–442 (2005).
   PubMedGoogle Scholar
• Knox J, Emmons R. Colesevelam for the treatment of bile acid diarrhea induced diarrhea in Crohn’s disease: patients intolerant of cholestyramine. Gastroenterology5, W1399 (2004).
   Google Scholar
• Berg C. Use of colesevelam hydrochloride (WelCholTM) as a novel therapeutic agent for the managment of refractory pruritus in chronic liver disease. Hepatology34, 541 (2001).
   Google Scholar
• Davidson MH, Dittakavi V, Bandari A et al. Colesevelam HCL decreases atherosclerosis and may activate reverse cholesterol transport in cholesterol fed rabbits. J. Appl. Res.6, 4–13 (2006).
   Google Scholar